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Abstract Two single-site, laboratory, negatively controlled,
masked, randomised dose confirmation studies were per-
formed: one in dogs, the other in cats. After a period of accli-
matisation, both the dogs and cats were orally infected with
Echinococcus multilocularis protoscoleces. In the dog study,
10 dogs received a single dose of Milpro® tablets at a mini-
mum dose of 0.5 mg/kg milbemycin oxime and 5 mg/kg
praziquantel 18 days post-infection and 10 dogs received no
treatment. In the cat study, 10 cats received a single dose of
Milpro® tablets at a minimum dose of 2 mg/kg milbemycin
oxime and 5 mg/kg praziquantel 7 days post-infection, 10 cats
received a single dose of the treatment 18 days post-infection
and 10 cats remained untreated. In both studies, intestinal
worm counts were performed 23 days post-infection at nec-
ropsy. No worms were retrieved from any of the 30 treated
animals. Nine of 10 control dogs had multiple worms (geo-
metric mean 91, arithmetic mean 304) and all 10 control cats
had multiple worms (geometric mean 216, arithmetic mean
481). The difference in worm counts between all three treated
groups and their controls was highly significant (ANOVA p
values of log transformed data <0.0001). Efficacy of 100 %
was demonstrated for the elimination of adult E.
multilocularis in dogs and cats as well as for elimination of
immature E. multilocularis in cats as evidenced by the effec-
tiveness of treatment 7 days post-infection. The treatments
were well accepted and tolerated, and there were no adverse
drug reactions observed.
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Introduction
Echinococcus multilocularis is one of the small cestodes of
the Echinococcus genus in the family of Taeniidae, which has
a widespread distribution in the northern hemisphere and
whose known distribution is increasing in Europe and else-
where (Eckert and Deplazes 1999; Romig et al. 1999;
Wahlstrom et al. 2011). The definitive hosts for this tapeworm
are carnivores, generally canids (foxes, wolves, coyotes) and
the principle wild definitive host in Europe is the Red Fox
(Jenkins and Romig 2000), but felids can also act as definitive
hosts (Deplazes et al. 1999, Jenkins and Romig 2000).
Consequently both domestic dogs and cats can harbour patent
infections (Dyachenko et al. 2008). There has been some de-
bate about the role domestic cats may play in the epidemiol-
ogy of the infection (Kapel et al. 2006). E. multilocularis
worms resulting from both, experimental and natural infec-
tions in cats can produce thick-shelled eggs, and therefore,
cats should be considered as hosts and a source of potential
infection (Thompson et al. 2003). Due to the small size of the
adult worms and their relatively small nutrient requirements,
overt clinical signs associated with the parasite in the defini-
tive host species are unusual, generally minor in nature (intes-
tinal upsets) and are thought to occur only when the worm
burdens are very high. In the definitive host, the developing
and adult worms inhabit the small intestine and proglottids
separate from the worm, pass through the bowel and are
* Dejan Cvejic
dejan.cvejic@klifovet.com
1 KLIFOVETAG, Geyerspergerstr. 27, 80689 Munich, Germany
2 Clinvet International Ltd, Bloemfontein, Republic of South Africa
3 Medical and R&D Department, Virbac SA, Carros Cedex, France
Parasitol Res (2016) 115:1195–1202
DOI 10.1007/s00436-015-4855-7
excreted in and around faecal matter. For completion of the
lifecycle, mammalian intermediate hosts transmit the larval
form of the parasite (i.e. metacestode) by ingesting embryo-
nated eggs which develop into onchospheres that migrate
through body tissues via blood vessels and then settle in or-
gans. The metacestode then develops as a continuously grow-
ing tumour-like polycystic mass that is not clearly separated
from the host tissues. Developed protoscoleces are found
within these multiple cysts, which when ingested by the de-
finitive host develop into adult worms. Many species, primar-
ily small rodents, can fulfil this intermediate host role, e.g.
mice, rats, voles, and shrews. Humans can be included in this
list as a potential intermediate host, although the human being
might be better described as a Bdead-end or incidental host^,
in that relatively few humans will be ultimately eaten by de-
finitive hosts. However, the zoonotic risk posed by this spe-
cies of worm is considerable, in that, ingestion of embryonat-
ed eggs passed by definitive hosts results in the development
of alveolar echinococcosis in man (also known as alveolar
hydatidosis), which is considered to be the most serious par-
asitic disease in humans in Europe (Romig 2009) with a prev-
alence of <1.4 per 100,000 population (Ammann et al. 2001).
In the absence of a successful treatment, which is difficult to
achieve, the condition has a fatal outcome. Close social con-
tact between humans and infected domestic dogs and cats is
likely to be an increased risk factor for alveolar
echinococcosis as demonstrated by Kreidl et al. (1998) who
identified an associated increased risk with both cat ownership
and hunting. Petavy et al. (2000) proposed that the prevalence
of E. multilocularis in the domestic cat in an endemic area of
alveolar echinococcosis is a risk factor for human beings,
especially veterinarians. Consequently, despite not appearing
to be overtly detrimental to the health of domestic dogs and
cats, vigilant prevention of E. multilocularis infections in do-
mestic dogs and cats in endemic areas together with surveil-
lance, i.e. screening and monitoring the prevalence in certain
wildlife species, is necessary in order to reduce the risks of
human infection and further spread of the parasite.
Additionally, dogs living in endemic areas of the E.
multilocularis, having access to rodents, should be treated at
4-week intervals with an effective anthelmintic containing
praziquantel or epsiprantel in order to prevent zoonosis
(ESCCAP Guideline 01 Second Edition 2010).
Milpro® tablets are new formulations containing
milbemycin oxime and praziquantel as active ingredients.
Milbemycin oxime is a macrocyclic lactone. The efficacy of
milbemycin oxime has long been established against intestinal
nematodes, pulmonary and cardiac helminths including heart-
worm larvae and arachnids. It is ineffective as a treatment
against cestodes.
Praziquantel, an acylated isoquinoline pyrazine compound,
has been demonstrated to have cestocidal effects on both ju-
venile and adult worms for 40 years (Thomas and Andrews
1976; Thomas and Gonnert 1978). In cats and dogs,
praziquantel at 5 mg/kg has proved effectiveness against both
immature and adult E. multilocularis as well as many other
species of cestodes (Thomas and Gonnert 1978). Praziquantel
is effective at extremely low concentrations if it comes into
contact with the parasite (Thomas and Andrews 1976).
Praziquantel acts directly on contact with the parasites tegu-
ment and damages the structure (Markovki et al. 2006) as well
as affects its carbohydrate metabolism and disrupts calcium
homeostasis and membrane permeability to calcium ions in
the parasite (Greenberg 2005) thereby resulting in tetanic con-
traction of the parasites’ musculature and subsequent
tegumental disintegration.
The combination of milbemycin oxime with praziquantel
does not reduce the efficacy of praziquantel against E.
multilocularis (Jenkins and Romig 2003).
Although there are orally administered milbemycin oxime/
praziquantel combination products with the same concentra-
tions of actives approved for the veterinary market, there is the
regulatory requirement to perform clinical efficacy studies.
Because of the nature of E. multilocularis and the inherent
zoonotic risk of working with this parasite, strictly controlled
terminal laboratory studies using experimental infections have
to be performed. For effective control of such a parasite it is
essential to achieve 100 % efficacy.
Materials and methods
Both studies were performed at the same laboratory in
compliance with the International Cooperation on
Harmonisation of Technical requirements for Registration
of Veterinary Medicinal Products (VICH) guideline 9 for
Good Clinical Practice (VICH 2001a). The studies follow-
ed also the applicable other VICH guidance documents:
BEfficacy requirements for anthelmintics: Overall
guidelines^ (VICH 2000), BEffectiveness of anthelmintics:
Specific recommendations for canine^ (VICH 2001b) and
BEffectiveness of anthelmintics: Specific recommendations
for feline^ (VICH 2001c). The protocol was subjected to
review and satisfy both the sponsor’s and the laboratory’s
animal welfare and ethical committees as well as satisfy
the applicable national standard for BThe care and use of
animals for scientific purposes^ (SABS 2008) and the lo-
cal regulatory requirements.
Masking of personnel responsible for collecting assess-
ment data to treatment allocation was enabled by the use of
unmasked dispensers that played no other part in study
procedures.
Animal selection
Both dogs and cats were vaccinated and de-wormed prior to
pre-selection and the commencement of acclimatisation. The
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dogs underwent a clinical examination 4 days prior to infec-
tion on day 0, and the cats were clinically examined on day
−14, 14 days prior to infection. These clinical examinations
formed part of the selection process for continued participa-
tion in the study.
Dogs and cats were selected if:
& they had been acclimated to the study site for at least
7 days.
& they were clinically healthy as verified by a veterinarian
during acclimatisation.
& they were older than 8 weeks of age.
& they were not pregnant.
& they had been de-wormed prior to acclimatisation, and
they were free from any resident helminth infections as
determined by gross and microscopic faecal examination
prior to experimental infection.
& they were not fractious.
Although the animals were housed individually throughout
the study, they were able to see and Binteract^ with conspe-
cifics. Their faeces and pens/cages were observed throughout
acclimatisation for evidence of helminth infection including a
microscopic qualitative faecal flotation assessment during
acclimatisation.
Animal welfare and safety assessments
Beside clinical examinations performed on dogs (day −19)
and cats (days −25, −12 and −1), from the commencement
of acclimatisation (day −25) until the end of the in-life phase
of the study (day 5), general health observations (GHOs) were
made daily for all animals. Multiple additional health obser-
vations were made on the days of infection and dosing.
Animals were controlled for the occurrence of adverse events
(AEs); an AE is defined as Bany observation in animals that is
unfavourable and unintended and that occurs after the use of a
veterinary product or investigational veterinary product
(Milpro®), whether or not considered to be product related^
(VICH 2001a).
Macroscopic post-mortem examination of all animals was
performed at the time of worm retrieval at necropsy.
Animal infection with protoscoleces
Food was withdrawn from both dogs and cats on the afternoon
of the day prior to experimental infection. Approximately 1 h
prior to experimental infection, the cats were provided with
10–15 g of soft food. The dogs and cats received their normal
feed approximately 2 h after the oral administration of the
protoscoleces.
The infective material for both studies was stored in an
antibiotic saline solution and derived from European isolates
less than 10 years old, which had been passaged through voles
and/or gerbils. The percentage viability of the protoscoleces
was evaluated microscopically, based onmovement and flame
cell activity. Based on the percentage viability, protoscoleces
counts and the pre-defined dilution, the infective doses were
prepared consisting of approximately 15,000 protoscoleces in
1.4 mL for each dog and approximately 20,000 protoscoleces
in 3 mL for each cat. These infective doses were administered
by syringing the solution into the back of the oral cavity.
Immediately, after administration, the dogs and cats received
a further 1.4 and 3 mL of saline, respectively, to ensure effec-
tive administration of the infective dose.
Animals were observed immediately after administration
and at 1 h (± 10 min) post-infection to check that there was
no regurgitation and/or vomiting of the infective doses.
The experimental infection was performed applying the
method described by Jenkins and Romig (2000).
Animal randomisation to treatment groups
Twenty dogs and 30 cats were selected for further study par-
ticipation on day −19. Eligible dogs and cats in excess of 20
and 30, respectively, were withdrawn from the study in a
randomised fashion. Dogs were randomised to treatment
groups on day −1 and cats on day −12. Animals were first
separated by gender and then ranked within gender, from
the highest to lowest body weight; ascending order of
identification numbers was used for tie breaking.
Animals were blocked in 10 replicates of two in dog,
and 10 replicates of three in cat study so that there were
two balanced treatment groups of 10 dogs and three bal-
anced treatment groups of 10 cats.
Animal dosing
Dogs were dosed with tablets containing 2.5 mg milbemycin
oxime and 25 mg praziquantel or 12.5 mg milbemycin oxime
and 125 mg praziquantel and Milpro® film-coated tablets for
small dogs and puppies and Milpro® film-coated tablets for
dogs. Cats were dosed with Milpro® film-coated tablets for
small cats and kittens (see Tables 1 and 2)
The doses administered were in accordance with the
Summary of Product Characteristics (SPC) of the respective
product using the body weights measured and recorded the
day prior to dosing (day −1 for dogs and days −12 and −1 for
cats). Tablets were administered at the back of the oral cavity
over the base of the tongue and ensured that they were
swallowed. Immediately, post-dosing the oral cavity was
checked to see that the tablet(s) had been swallowed. Each
animal was observed intermittently for the first hour post-
dosing and then hourly (± 15 min) for up to 4 h.
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Worm retrieval and counting
Food was removed from the pens/cages on the afternoon of day
4; on day 5, all animals were euthanized. After laparotomy, the
small intestine was ligated proximal of the pylorus and distal of
the ileocaecocolic junction. The small intestine was then re-
moved in its entirety, incised longitudinally and placed in a warm
water bath (approximately 37 ° C) for at least an hour. The
intestine was then gently rinsed and rubbed between two fingers
to dislodge worms that were still attached. Finally the mucosal
lining was gently scraped using a microscope slide or suitable
alternative to ensure that all worms were removed from the mu-
cosal lining. The intestinal contents and all washings were passed
through a sieve with aperture size of 75 μm. The residue collect-
ed in the sieve was gently back-washed into a container labelled
with the animals’ identity, and the contents were preserved in
10 % formalin. After the samples had been collected a stereomi-
croscope was used for performing worm counts. The number of
scoleces was considered to be the Bworm count^.
Procedures for worm retrieval were performed on a treat-
ment group basis, with thorough cleaning of facilities and
equipment between groups in order to prevent the risk of
Bcross contamination^. The method applied was based on
the one described by Jenkins and Romig (2000).
Results
Animal selection
Twenty-six dogswere pre-selected for the study and acclimatised
to the study environment. Of the 26 dogs, 2 of them did not
satisfy the inclusion criteria; 1 dog was listless and was excluded
for health reasons, the other dog was found to be infected with
Trichuris vulpis on day −20 when microscopic faecal examina-
tion was performed. Four dogs were withdrawn in a randomised
fashion, leaving 20 dogs to be allocated to two treatment groups
of 10 dogs. The ages of the selected dogs ranged from2.8months
to 6.6 years; their body weights on day −1 ranged from 4 to
30 kg, and 14 of the dogs were females and six were males.
Forty cats were pre-selected for the study. At the commence-
ment of acclimatisation on day −25, four cats were withdrawn
for health reasons. On day −7, one cat showed diarrhoea; de-
spite treatment, the cat died the following day (day −6). On day
−2, one cat was not weight bearing on its left hind limb and was
withdrawn from the study on day −1. During acclimatisation,
no cat was identified having any helminth infections. Four cats
were withdrawn on day −1 in a randomised fashion leaving 30
cats (21 males and 9 females) to be allocated to the three treat-
ment groups of 10 cats. The ages of the selected cats ranged
from 10 to 24 weeks. The body weights of the selected cats on
day 6 ranged from 0.55 to 1.8 kg.
Animal welfare and safety assessments
NoAEwas recorded in the dog study. One cat was recorded to
be thin on day −1. This cat was a young growing adolescent
that had in fact gained 30 g body weight between day −12 and
day −1. This cat had received Milpro® on day −11. There
were no animal health problems in either study in the periods
between experimental infection and dosing with Milpro®;
therefore, no concomitant treatments were applied.
All cats enrolled received prophylactic medication for coc-
cidiosis with Baycox® 5 % solution per os and Purbac® tab-
lets per os. The dogs and cats not enrolled onto the study
received appropriate veterinary care.
At post-mortem examination, no macroscopic abnormali-
ties were evident in any of the 20 dogs and 30 cats, other than
those strictly related to the parasitic infection.
Animal infection with protoscoleces
The experimental infection withE. multilocularis proved to be
successful in both studies; all control animals barring one dog
Table 1 Dosing table for dogs
Body
weight (kg)
Number of small dog/puppy
equivalent tablets (2.5mg milbemycin
oxime/25mg praziquantel)








Table 2 Dosing table for cats
Body weight (kg) Number of Milpro®
film-coated tablets for
small cats and kittens
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harboured multiple E. multilocularis worms on day 5. There
were no reports of regurgitation/vomiting post-infection.
Animal randomisation to treatment groups
The randomisation programme resulted in well balanced treat-
ment groups with respect to gender and body weight in both
studies.
In the dog study, there were seven females and three males
in each treatment group, and the arithmetic mean body weight
for group 1 (untreated controls) was 11.05 kg and for group 2
was 12.24 kg. Despite the range of ages (2.8 months–
6.6 years), the two treatment groups were well balanced with
respect to age, with seven of the 10 Group 1 dogs being
<5.3 months old and six of the Group 2 dogs being
<5.3 months old.
In the cat study, there were seven males and three females
in each of the three treatment groups, and the arithmetic mean
body weights for each treatment group were 1.218 kg (median
1.195 kg) in the first group, 1.193 kg (median 1.175 kg) in the
second and 1.232 kg (median 1.175 kg) in the third one.
Animal dosing
None of the 30 animals dosed (10 dogs and 20 cats) with
Milpro® had any apparent reaction to the dosing procedure
or the tablets themselves. The treatment was well accepted and
tolerated; no tablets were rejected and dosing was complete
and in accordance with dose rates indicated in the protocol and
SPCs of the products.
Worm counts
No worms were found in any of the Milpro®-dosed animals.
Multiple worms (exclusively E. multilocularis) were found in
all of the control animals besides one dog (see Tables 3 and 4).
The geometric mean of worm counts in control dogs was 91
(arithmetic mean was 304), and the geometric mean worm
count in control cats was 216 (arithmetic mean was 481).
The efficacy of the milbemycin oxime/praziquantel combina-
tions proved to be 100 % against adult E. multilocularis in-
fection in dogs and 100 % against adult and immature E.
multilocularis infections in cats with the differences between
all treated groups and their controls being highly significant at
0.0001 (ANOVA p value log transformed).
Discussion
Praziquantel either alone or in combination, in different for-
mulations and when administered by a variety of routes, has
been demonstrated to be highly effective in the treatment of a
wide variety of cestode infections in dogs and cats (e.g.
Thomas and Andrews 1976; Guralp et al. 1976; Anderson et
al. 1978; Thomas and Gonnert 1978; Anderson et al. 1981;
Jenkins and Romig 2000; Jenkins and Romig 2003; Derbala et
al. 2007; Altreuther et al. 2009; Papini et al. 2010; Tuzer et al.
2010; Barnett et al. 2013, etc.). Despite its long-term use
against Dipylidium caninum over a 40-year period, it does
not appear that resistance has developed to the drug (Barnett
et al. 2013) with 100 % efficacy at 5 mg/kg, it is unlikely that
there will be tapeworms surviving to pass on resistance.
Vokral et al. (2012) have shown that the Brat tapeworm^
(Hymenolepis diminuta), as a representative cestode, is not
able to deactivate praziquantel and as such its biotransforma-
tion enzymes are not able to contribute to the development of
resistance to praziquantel. As recently as 2015, the combina-
tion of milbemycin oxime and praziquantel has been reported
to be the optimum choice for the treatment and prevention of
helminth infections in kennel dogs under field conditions
(Rinaldi et al. 2015).
The studies reported here were designed to confirm the
efficacy of a combination dose of 5 mg/kg praziquantel and
0.5 mg/kg milbemycin in dogs and 5 mg/kg praziquantel and
2 mg/kg milbemycin in cats against E. multilocularis infec-
tions. This necessitates experimental infections of the host. It
has been reported that cats are not as suitable as experimental
hosts for this parasite as dogs are (Anderson et al. 1981) and
that worm recovery in dogs was significantly greater than in
cats (Thompson et al. 2003). However, in the cat study report-
ed here, all control animals had multiple worms, demonstrat-
ing reliable infection, and therefore, necessary to adequate
Echinococcus control in cats living in endemic areas.
The E. multilocularis worm burden in subadult foxes is
significantly higher than the one seen in adults (Hofer et al.
2000). This suggests that previous exposure to the parasite
may stimulate some immune response, effecting a degree of
control. The existence of host humoral immune responses in
helminths has been suggested by many studies such as those
performed by Gallie and Sewell (1983) as well as by
Hrckova et al. (2007)). Young, previously naive (with
respect to E. multilocularis infection) animals were in-
cluded in all treatment groups in both studies reported
here. The genders, body weights and ages of the animals
in each treatment group, in each of the studies, were rea-
sonably balanced, enabling unbiased assessments of post-
dosing worm burdens.
Neither of the two control groups was Bdosed^ with place-
bo. However, it is unlikely that the oral administration of a
placebo tablet would have resulted in a Bstress^ reaction that
would affect worm burden positively or negatively, thereby
biasing results. The studies were essentially dose-
confirmation studies of the Milpro® formulations, tested in a
well-established artificial infection model; the authors, there-
fore, consider that there was no relevant bias introduced by not
treating the control animals with placebo. All observations
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were done by fully masked personnel, in order not to intro-
duce any further bias.
No adverse event occurred and no concomitant drugs prior
to the act of euthanasia were used in the animals enrolled in
the study. Drugs for the prophylactic treatment of coccidiosis
were administered to all cats. The prophylactic use of a prod-
uct to prevent coccidian-related disease is a standard treatment
in young puppies in the research facility; these drugs are not
considered to have any cestocidal effect and none of the cats
that were experimentally infected had diarrhoea due to coc-
cidiosis or any other cause which might have resulted in ex-
pulsion of worms. These facts together with the finding that all
control cats had multiple worms after necropsy indicate that
this concomitant treatment did not interfere with the validity
of the study results.
The control of Echinococcus species of helminths is a par-
ticular challenge in part due to the zoonotic risks (referred to in
the introduction, with respect to E. multilocularis) and the
finding that they require higher doses of anthelmintics than
some of the other species of cestodes commonly found in dogs
and cats. Fortunately, praziquantel has a very wide therapeutic
index at 5 mg/kg, which is the indicated dose and which is
sufficient to achieve 100 % efficacy against E. multilocularis
and E. granulosus. Efficacy of 100 % is not only desirable,
especially with a parasite such as E. multilocularis but also
necessary in order to avoid endemic infection and to reduce
the risk of developing drug resistance. The studies reported
here demonstrated 100 % efficacy of the praziquantel compo-
nent of the combination product against adult E.
multilocularis in dogs and cats.
No adverse event was reported in either study. Praziquantel
at a minimum dose of 5 mg/kg was demonstrated to be safe as
well as effective.
The prevalence of cestode infection is underestimated by
gross and microscopic faecal examination (Adolph et al.
2011) and even though immunologically associated assays
have been and are being developed (Deplazes et al. 1999)
for the purpose of control, it is probably better to utilise a
regular prophylactic anthelmintic programme, rather than rely
on identification and diagnosis prior to dosing. Praziquantel,
being component of the broad spectrum milbemycin/
praziquantel combination used in these studies, serves this
aim well, demonstrating 100 % efficacy against E.
multilocularis, found in dogs and cats at the dose of 5 mg/kg.
Conclusions
The experimental infection of both dogs and cats with E.
multilocularis protoscoleces was successful.
A single oral dose of Milpro® film-coated tablets for dogs
and Milpro® film-coated tablets for small dogs and puppies
was demonstrated to be a safe and 100 % effective treatment
Table 3 E. multilocularis











Geometric mean 91 0
Arithmetic mean 304 0
ANOVA test for superiority p<0.0001









on Day −11) n=10
Group 3 (juveniles)
(Milpro® on Day 0)
n=10
Median 461.5 0 0
Minimum 5 0 0
Maximum 1470 0 0
Geometric Mean 216 0 0
Arithmetic Mean 481 0 0
ANOVA test for superiority p<0.0001 Group 1 compared to Group 2 or Group 3)
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against E. multilocularis in dogs when administered at a dose
rate of 5 mg/kg indicated in the products’ SPCs.
A single oral dose of Milpro® film-coated tablets for
small cats and kittens was demonstrated to be a safe
and 100 % effective treatment against both immature
(7 days post-infection) and adult E. multilocularis in
young cats when administered at the recommended dose
of 5 m/kg as indicated in the product’s current SPC for
other tapeworm species.
The minimum dose of 5 mg/kg praziquantel used in these
studies proved to be safe and 100 % effective against adult E.
multilocularis in dogs and immature and adult E.
multilocularis in cats.
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